SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056959
Filing Date
2024-05-09
Accepted
2024-05-09 16:11:14
Documents
69
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q atra-20240331.htm   iXBRL 10-Q 2032975
2 EX-10.1 atra-ex10_1.htm EX-10.1 29979
3 EX-31.1 atra-ex31_1.htm EX-31.1 13382
4 EX-31.2 atra-ex31_2.htm EX-31.2 13419
5 EX-32.1 atra-ex32_1.htm EX-32.1 9726
  Complete submission text file 0000950170-24-056959.txt   7707153

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atra-20240331.xsd EX-101.SCH 1238661
73 EXTRACTED XBRL INSTANCE DOCUMENT atra-20240331_htm.xml XML 1071840
Mailing Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320
Business Address 2380 CONEJO SPECTRUM ST SUITE 200 THOUSAND OAKS CA 91320 805-623-4244
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36548 | Film No.: 24930700
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)